A hypoxia-activated photothermal agent inhibits multiple heat shock proteins for low-temperature photothermal therapy

Area of Science:

• Biomedical Engineering
• Materials Science
• Oncology

Background:

• Heat shock proteins (HSPs) play a crucial role in cancer cell survival and resistance to therapy.
• Photothermal therapy (PTT) offers a promising approach for cancer treatment by using heat to induce cell death.
• Hypoxic conditions are common in solid tumors and can influence treatment efficacy.

Purpose of the Study:

• To synthesize a near-infrared (NIR) organic photothermal agent (PTA) capable of inhibiting heat shock proteins (HSPs).
• To investigate the agent's activation under hypoxic conditions for low-temperature photothermal therapy (PTT) of cancer.

Main Methods:

• Synthesis of a novel NIR organic photothermal agent.
• In vitro evaluation of the agent's ability to inhibit specific heat shock proteins.
• Assessment of the agent's photothermal conversion efficiency under NIR irradiation.
• Testing the efficacy of low-temperature PTT under simulated hypoxic tumor conditions.

Main Results:

• Successful synthesis of an NIR organic PTA with potent photothermal conversion capabilities.
• Demonstrated inhibition of key heat shock proteins by the PTA.
• Effective activation of the PTA under hypoxic conditions.
• Significant cancer cell death observed with low-temperature PTT using the developed agent.

Conclusions:

• The developed NIR organic PTA is effective in inhibiting HSPs and can be activated under hypoxia.
• This agent holds potential for low-temperature photothermal therapy in hypoxic tumors.
• Further research is warranted to explore its clinical applicability in cancer treatment.